Toray, Japan Tobacco, Torii Pharmaceutical Agree to Co-Develop and Market New Antipruritus Drug in Hemodialysis Patients
Hemodialysis-related uremic pruritus is a condition that causes systemic and severe itching, without inflammation, on the skin and its cause has not yet been clearly elucidated. Hemodialysis patients with uremic pruritus suffer lack of sleep due to severe itching, which not only deteriorates their quality of life (QOL) but also is one of the causes of worsening of systemic condition. It is known that this type of itching is not relieved by conventional antipruritic drugs such as antihistamine agents, and the development of effective medicines has long been awaited.
TRK-820 is a compound that aims to treat uremic pruritus in patients on hemodialysis. This compound is a selective kappa opioid receptor agonist and is expected to be effective with a novel mechanism in treating itching that is resistant to existing treatments such as antihistamine agents.
The drug has entered the final phase of its clinical trials before application in Japan and further development would be jointly carried out by Toray and the JT group, with marketing to be handled by Torii.
Organizations
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.